Efficacy of Intrarectal Versus Intravenous Quinine for the Treatment of Childhood Cerebral Malaria
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00124267|
Recruitment Status : Unknown
Verified July 2005 by Makerere University.
Recruitment status was: Active, not recruiting
First Posted : July 27, 2005
Last Update Posted : August 4, 2005
|Condition or disease||Intervention/treatment||Phase|
|Cerebral Malaria||Drug: Intrarectal quinine||Phase 3|
Cerebral malaria is the most lethal complication of P.falciparum infection with a mortality rate between 5 and 40%. Intravenous quinine remains the recommended treatment for cerebral malaria. However its administration is often not feasible due to lack of simple equipment or trained staff. When referral is not possible, a viable alternative is needed. The intrarectal route is of interest in children since it is painless and simple. A few studies in Francophone Africa have reported clinical efficacy and tolerance of intrarectal quinine. Although the studies were randomized trials, they were not blinded and did not use the WHO definition of cerebral malaria as selection criteria.
The current study aims to establish whether intrarectal quinine is as effective and as safe as intravenous quinine in the treatment of childhood cerebral malaria.
To address the shortcomings of the Francophone African studies, the investigators have designed a randomized, double blind placebo controlled clinical trial to include patients who meet the WHO definition of cerebral malaria.
Intrarectal quinine (15mg/kg every 8 hours) given to children with cerebral malaria, will lead to a shorter parasite clearance time (39.9 hours) than intravenous quinine (55.0 hours).
The investigators calculated a sample size of 54 patients in each group for 90% power and 95% confidence. In the calculation, the researchers assumed that the children receiving intrarectal quinine would have a mean parasite clearance time of 39.9 (SD 24.3) hours and those receiving intravenous quinine would have a mean parasite clearance time of 55.0(SD 24.3) hours (27.5% effect size), according to a study by Aceng, Byarugaba and Tumwine in the same hospital.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||108 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Efficacy of Intrarectal Versus Intravenous Quinine for the Treatment of Childhood Cerebral Malaria: a Randomized Clinical Trial|
|Study Start Date :||September 2003|
|Study Completion Date :||January 2004|
- Parasite clearance time
- Fever clearance time
- Coma recovery time
- Time to sit unsupported
- Time to begin oral intake
- Neurological sequelae
- Adverse drug events
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00124267
|Kampala, Uganda, 7051|
|Principal Investigator:||Jane Achan, MBChB||Department of Paediatrics and Child Health, Makerere University|